Taiwan Advance Bio-Pharmaceutical Inc. announced earnings results for the full year ended December 31, 2018. For the full year, the company announced sales was TWD 63.038 million compared to TWD 56.119 million a year ago. Operating loss was TWD 154.774 million compared to TWD 103.828 million a year ago. Net loss was TWD 133.196 million compared to TWD 98.407 million a year ago. Basic loss per share was TWD 2 compared to TWD 1.64 a year ago.